Ferumoxides-enhanced quantitative magnetic resonance imaging of the normal and abnormal bone marrow: Preliminary assessment

Journal of Magnetic Resonance Imaging

Volumn 9, Issue 2, 1999, Pages 322-328

  Vande Berg, B C ^a   Lecouvet, F E ^a   Kanku, J P ^a   Jamart, J ^b   Van Beers, B E ^a   Maldague, B ^a   Malghem, J ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

Bone marrow; Contrast media; Iron; MRI; Neoplasm

Indexed keywords

SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CASE REPORT; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DISTRIBUTION; FEMALE; HUMAN; IMAGE QUALITY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CANCER; LUMBAR SPINE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; SPINE METASTASIS; SPINE RADIOGRAPHY;

ADULT; AGED; BONE MARROW; BONE MARROW NEOPLASMS; CONTRAST MEDIA; FEMALE; HUMANS; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OXIDES; SUSPENSIONS;

EID: 0033007863     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-2586(199902)9:2<322::AID-JMRI26>3.0.CO;2-M     Document Type: Article

References (41)

1. Weissleder R, Stark DD, Engelstad BL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. Am J Roentgenol 1989; 152(1):167-173.
2. Weissleder R, Papisov M. Pharmaceutical iron oxides for MR imaging: reviews of magnetic resonance in medicine 1992;4:1-20.
3. Wisse E, Knool DL, McCuskey RS. A transmission electron microscopy study on the uptake of AMI-25 by sinusoidal cells. In: Wisse E, Doucet D. Van Bossuyt H, editors. Cells of the hepatic sinusoid, 1st ed. Leiden, the Netherlands: Kupffer Cell Foundation; 1991. p 534-539.
4. Weissleder R, Liver MR imaging with iron oxides: toward consensus and clinical practice. Radiology 1994;193(3):593-595.
5. Petersein J, Saini S, Weissleder R. Iron oxide-based reticuloendothelial contrast agents for MR imaging: clinical review. Magn Reson Imaging Clin North Am 1996;4(1):53-60.
6. Van Beers BE, Gallez B, Pringot J. Contrast-enhanced MR imaging of the liver. Radiology 1997;203:297-306.
7. Seneterre E, Weissleder R, Jaramillo D, et al. Bone marrow: ultrasmall superparamagnetic iron oxide for MR imaging. Radiology 1991;179(2):529-533.
8. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990:175 / 494-498.
9. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990;175:489-493.
10. Saini S, Stark DD, Hahn PF, Wittenberg J, Brady TJ, Ferrucci JT Jr. Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system. Radiology 1987;162:211-216.
11. Gandon Y, Heautot J, Brunet F, Guyader D, Deugnier Y, Carsin M. Superparamagnetic iron oxide: clinical time-response study. Eur J Radiol 1991;12:195-200.
12. Bellin MF, Zaim S, Auberton E, et al. Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. Radiology 1994;193:657-663.
13. Vande Berg BC, Schmitz PJ, Scheiff JM, et al. Acute myeloid leukemia: lack of predictive value of sequential quantitative MR imaging during treatment. Radiology 1995;197:301-305.
14. In Den Kleef JJE, Cuppen JJM. RLSQ: T1, T2, and p calculations, combining ratios and least squares. Magn Reson Med 1987;5:513-524.
15. Vogler JB, Murphy WA. Bone marrow imaging. Radiology 1988; 168(3):679-693.
16. Daffner RH, Lupetin AR, Dash N, Deeb ZL. MRI in the detection of malignant infiltration of bone marrow. Am J Roentgenol 1986;146: 353-358.
17. Jones KM, Unger EC, Granstrom P, Seeger JF, Carmody RF, Yoshino M. Bone marrow imaging using STIR at 0.5 and 1.5 T. Magn Reson Imaging 1992;10(2):169-176.
18. Fletcher BD, Wall JE, Hanna SL. Effect of hematopoietic growth factors on MR images of bone marrow in children undergoing chemotherapy. Radiology 1993;189(3):745-751.
19. Mirowitz SA, Apicella P, Reinus WR, Hammerman AM. MR imaging of bone marrow lesions: relative conspicuousness on T1-weighted, fat-suppressed T2-weighted, and STIR images. Am J Roentgenol 1994;162(1):215-221.
20. Schuck JE, Czarnecki DJ. MR detection of probable hematopoietic hyperplasia involving the knees, proximal femurs, and pelvis. Am J Roentgenol 1989;153(3):655-656.
21. Levine CD, Schweitzer ME, Ehrlich SM. Pelvic marrow in adults. Skeletal Radiol 1994;23(5):343-347.
22. Moore SG, Bisset GS, Siegel MJ, Donaldson JS. Pediatric musculoskeletal MR imaging. Radiology 1991;179(2):345-360.
23. Caldemeyer KS, Smith RR, Harris A, et al. Hematopoietic bone marrow hyperplasia: correlation of spinal MR findings, hematologic parameters, and bone mineral density in endurance athletes. Radiology 1996;198(2):503-508.
24. Stevens SK, Moore SG, Kaplan ID. Early and late bone-marrow changes after irradiation: MR evaluation. Am J Roentgenol 1990; 154(4):745-750.
25. Stevens SK, Moore SG, Amylon MD. Repopulation of marrow after transplantation: MR imaging with pathologic correlation. Radiology 1990;175(1):213-218.
26. Kaplan PA, Asleson RJ, Klassen LW, Duggan MJ. Bone marrow patterns in aplastic anemia: observations with 1.5-T MR imaging. Radiology 1987;164(2):441-444.
27. De Bruyn PP, Breen PC, Thomas TB. The microcirculation of the bone marrow. Anat Rec 1970;168(1):55-68.
28. DeBruyn P, Michelson S, Becker R. Endocytosis, transfer tubules and lysosomal activity in myeloid sinusal endothelium. J Ultrastruct Mol Struct Res 1975;53:133-151.
29. De Bruyn PPH. Structural substrates of bone marrow function. Semin Hematol 1981;18(3):179-193.
30. Jung CW, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995;13(5):661-674.
31. Majumdar S, Zoghbi S, Pope CF, Gore JC. Quantification of MR relaxation effects of iron oxide particles in liver and spleen. Radiology 1988;169:653-655.
32. Gillis P, Koenig SH. Transverse relaxation of solvent protons induced by magnetized spheres: application to ferritin, erythrocytes, and magnetite. Magn Reson Med 1987;53:23-45.
33. Majumdar S, Zoghbi S, Pope CF, Gore JC. A quantitative study of relaxation rate enhancement produced by iron oxide particles in polyacrylamide gels and tissue. Magn Reson Med 1989;9:185-202.
34. Grangier C, Tourniaire J, Mentha G, et al. Enhancement of liver hemangiomas on T1-weighted MR SE images by superparamagnetic iron oxide particles. J Comput Assist Tomogr 1994;18(6):888-896.
35. Oswald P, Clement O, Chambon C, Schouman-Claeys E, Frija J. Liver positive enhancement after injection of superparamagnetic nanoparticles: respective role of circulating and uptaken particles. Magn Reson Imaging 1997;15:1025-1031.
36. Guimaraes R, Clement O, Bittoun J, Carnot F, Frija G. MR lymphography with superparamagnetic iron nanoparticles in rats: pathologic basis for contrast enhancement. Am J Roentgenol 1993;162: 201-207.
37. Chambon C, Clement O, Le Blanche A, Schouman Claeys E, Frija G. Superparamagnetic iron oxides as positive MR contrast agents: in vitro and in vivo evidence. Magn Reson Imaging 1993;11(4):509-519.
38. Caramella D, Jin XN, Mascalchi M, et al. Liver and spleen enhancement after intravenous injection of carboxydextran magnetite: effect of dose, delay of imaging, and field strength in an ex vivo model. MAGMA 1996;4(3-4):225-230.
39. Bulte JM, Vymazal J, Brooks RA, Pierpaoli C, Frank JA. Frequency dependence of MR relaxation times. II. Iron oxides. J Magn Reson Imaging 1993;3(4):641-648.
40. Majumdar S, Zoghbi SS, Gore JC. The influence of pulse sequence on the relaxation effects of superparamagnetic iron oxide contrast agents. Magn Reson Med 1989;10(3):289-301.
41. Tanimoto A, Pouliquen D, Kreft BP, Stark DD. Effects of spatial distribution on proton relaxation enhancement by particulate iron oxide. J Magn Reson Imaging 1994;4(5):653-657.